• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Keytruda - Articles and news items

FDA Merck approval head and neck cancer

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

keytruda

Merck releases new data for Keytruda at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells…

head-and-neck-cancer

FDA accepts sBLA for Keytruda in head and neck cancer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +